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Abstract
The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic
intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant
context, an activating PIK3CA mutation (H1047R) was knocked-in to an endogenous allele of the MCF10A non-tumorigenic
human breast epithelial cell line. Introduction of an endogenously mutated PIK3CA allele resulted in a marked epithelial-
mesenchymal transition (EMT) and invasive phenotype, compared to isogenic wild-type cells. The invasive phenotype was
linked to enhanced PIP3 production via a S6K-IRS positive feedback mechanism. Moreover, potent and selective inhibitors of
PI3K were highly effective in reversing this phenotype, which is optimally revealed in 3-dimensional cell culture. In contrast,
inhibition of Akt or mTOR exacerbated the invasive phenotype. Our results suggest that invasion is a core phenotype
mediated by increased PTEN/PI3K pathway activity and that therapeutic agents targeting different nodes of the PI3K
pathway may have dramatic differences in their ability to reverse or promote cancer metastasis.
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Introduction
Genetic deviations in the phosphatidylinoisitol 39-kinase (PI3K)
pathway have been detected in many human cancers [1] and are
thought to act primarily to stimulate cell proliferation and survival.
Two hotspot mutations reside in the helical domain of p110a and
a third is in the kinase domain. All three mutations have been
shown to provide a gain of function for the PI3K enzyme, and can
lead to increased downstream signaling through kinases such as
Akt and mTOR [2,3]. Genetic deletion or loss of function
mutations within the tumor suppressor PTEN, a phosphatase with
opposing function to PI3K, also increases PI3K pathway signaling
[4]. In addition, activation of the PI3K pathway results in feedback
down-regulation of pathway signaling, mediated by an mTOR/
S6K phosphorylation and inhibition of IRS-1 at Ser612 [5,6,7].
Epithelial-mesenchymal transition (EMT) is a program of gene
expression changes that leads to a dramatic shift in cell phenotype
towards a more invasive and migratory behavior [8,9]. The
contribution of specific cancer mutations towards EMT is still not
fully clear, and is confounded by the analysis of ectopic
overexpression models that do not reflect the endogenous
expression of mutated oncogenes. Studies in isogenic lines have
shown that transgenic approaches can over-estimate the gain of
function phenotypes induced by single cancer gene events
especially effects on cell proliferation [10,11].
In recent years gene targeting approaches have been utilized to
introduce mutations into human cell lines in a disease relevant
context [10,11]. In these studies, ‘knock-in’ cell lines harboring an
endogenous p110a kinase domain H1047R mutation were used to
precisely evaluate the functional consequences of a PIK3CA
mutation starting in a non-tumorigenic background. We found
that PIK3CA mutations increase PTEN/PI3K pathway signaling
and cell proliferation, but also promote EMT and cell invasion
and these phenotypes are sensitive to potent and selective PI3K
inhibitors. We also discovered that Akt or mTOR inhibition
enhanced morphologies associated with PTEN/PI3K pathway
signaling through feedback to PIP3.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36402Figure 1. Effects of the H1047R mutation on PI3K pathway signaling, cell viability and proliferation. (A) Analysis of PIP3 levels in
parental and knock-in clones. (B) Parental and knock-in clones were cultured with dose-titrated small molecule inhibitors and cell viability was
assessed after four days. (C) Parental and knock-in clones were cultured in the presence or absence of GDC-0941 dosed at an EC50 concentration for
the time points indicated and analyzed by Western blotting. (D) The parental and knock-in clones were cultured in the presence or absence of GDC-
0941 for 48 hours and proliferation was assessed in triplicate samples by BrdU labeling.
doi:10.1371/journal.pone.0036402.g001
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Cell culture
Parental and knock-in MCF10A clones (H1047R A and B) were
first published by Di Nicolantonio and colleagues [10] and were
licensed from Horizon Discovery Ltd. An additional set of
matched isogenic MCF10A parental PI3K mutant cells [12] were
obtained from Horizon Discovery to confirm results of 3-D culture
experiments. Cells were cultured in F12:DMEM 50:50 medium
supplemented with 20 ng/ml human EGF, 10 mg/ml insulin,
0.2 mg/ml hydrocortisone, 10% FBS, 100 units/ml penicillin,
2 mM L-glutamine, and 100 mg/ml streptomycin at 37uC under
5% CO2. MCF10A cells were typically passaged and maintained
in the presence of EGF and insulin. To detect differences with the
p110a H1047R and parental isogenic pairs, EGF and insulin were
absent from the media, except for those studies associated with 3-
D culture. Breast tumor cell lines were obtained from the
American Type Culture Collection (ATCC). Cell lines were tested
and authenticated using gene expression and single nucleotide
polymorphism genotyping arrays, as previously described [13,14].
Lines were cultured in RPMI or MEM supplemented with 10%
fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml
streptomycin at 37uC under 5% CO2.
Reagents
GDC-0941, PI3Ki-A/D, PI103 and erlotinib were from
Genentech, Inc. mTOR1/2i is from patent WO 2008/023159
A1 [15]. AKT1/2i (Inhibitor VIII) was from EMD Chemicals.
Human EGF, insulin, hydrocortisone and HActin antibodies were
from Sigma. Antibodies to phospho-Akt
Thr308, phospho-Akt
Ser473,
total Akt, Akt1, Akt2, phospho-PRAS40
Thr246, PRAS40, phospho-
S6
Ser235/236, phospho-GSK3b
Ser9, phospho-P70S6K
Thr389, phos-
pho-IRS1
Ser612 and mTOR were from Cell Signaling. The p110a
antibody was from BD Biosciences and the BrdU Proliferation
ELISA was obtained from Roche.
siRNAs and Transfections
mTOR and the non-targeting control siRNAs were from
Dharmacon and the p110a siRNA (GGACAACTGTTTCATA-
TAGTT) was from Genentech. The Akt siRNA inhibition kit,
which inhibits the expression of both Akt1 and Akt2 was obtained
from Cell Signaling. Transfection of siRNAs was accomplished
using an Amaxa Nucleofector Kit as described by the manufac-
turer for MCF10A cells.
Cell Viability Assays
Cells were seeded at 2000 cells/well in 384-well plates. Diluted
compounds were added to quadruplicate wells in 384-well cell
plates. After 4 days incubation, relative numbers of viable cells
were measured using CellTiter-Glo (Promega) and read with a
Wallac Multilabel Reader (PerkinElmer). EC50 values were
calculated using Prism 4.0 (GraphPad).
Protein Assays
Two million cells were seeded in a 10 cm
2 tissue culture plate
overnight. Cells were treated with an EC50 concentration of
inhibitors for the times indicated. Following treatment, cells were
washed with cold PBS and lysed in 16 Cell Extraction Buffer
(Biosource) supplemented with protease inhibitors (Roche), 1 mM
PMSF, and Phosphatase Inhibitor Cocktails 1 and 2 (Sigma). For
immunoblots, equal protein amounts were separated by electro-
phoresis through NuPage Bis-Tris 10% gradient gels (Invitrogen);
proteins were transferred onto PVDF membranes using the
Criterion system from Bio-Rad.
PIP3 Assay
The measurement of PIK3CA activity was carried out through
a PIP3 Mass Strip Kit or a PI3K kinase ELISA assay (Echelon
Biosciences) according to the manufacturer’s instructions.
BrdU Assay
Cells were seeded at 10,000 cells per well in a 96-well plate
overnight. After 48 hours of culture with the BrdU reagent, the
BrdU ELISA was performed according to the manufacturer’s
instructions (Roche) and the plate was read on an EnVision Plate
Reader (PerkinElmer).
Microarray Studies
Gene expression analysis was carried out on RNA extracted
from sub-confluent cell cultures using Qiagen RNeasy kits. RNA
samples of sufficient quality were profiled on Affymetrix
HGU133Plus_2.0 chips. Preparation of complementary RNA,
array hybridizations, scanning and subsequent array image data
analysis were done using the manufacturer’s specified protocol.
Gene expression data for experiments described in this study has
been deposited in the Gene Expression Omnibus (GEO) database
under accession number GSE17785.
3-Dimensional Cell Culture and Reagents
Acinar growth and morphogenesis assays in 3D laminin-rich
extracellular matrix (lrECM) were performed as described
previously [16,17]. Briefly, tissue culture dishes were coated with
a thin layer of growth factor-reduced Matrigel (BD Biosciences) on
ice and placed in a 37uC incubator for approximately 15 minutes
to allow for matrix polymerization. Cells were dislodged with
trypsin and resuspended in complete growth media containing
Table 1. Compounds used for viability and 3-D cell culture assays.
Compound ID Specificity Parental (EC50 mM) H1047R A (EC50 mM) H1047R B (EC50 mM)
GDC-0941 PI3K (p110a,b,d,c) 0.5 0.5 0.5
PI1103 PI3K (p110a,b,d,c), mTOR, DNA-PK 0.2 0.4 0.4
PI3Ki-A/D PI3K (p110a,d,c) 1.1 2 1.6
AKT1/2i Akt1, Akt2 .5 .5 .5
mTOR1/2i TORC1, TORC2 2.2 1.8 1.7
Erlotinib EGFR 4.3 .5 .5
Specificities and CellTiter-Glo viability assay EC50s for parental and H1047R clones.
doi:10.1371/journal.pone.0036402.t001
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mixing, cells were added to thepre-coated plates in the presence or
absence of inhibitors.
Quantification of Acinar Size and Shape
Size and shape values were determined from multiple phase-
contrast images as previously described [18]. An object’s shape
factor is defined as (4p*Area)/Perimeter
2). This results in a value
from 0 to 1, where 0 is a flat line and 1 is a perfect circle.
Matrigel Invasion Assay
Migration through matrigel was performed using Biocoat
Matrigel Invasion Chambers containing FluoroBlok inserts (BD
Biosciences). Cells were plated (35,000 total) and allowed to
migrate through matrigel for 24 hours according to the protocol
provided by the manufacturer. Number of invaded cells was
detected and quantified using ImageXpress (Molecular Devices).
Figure 2. MCF10A cells undergo EMT-like changes in the presence of a PI3K mutation. (A) Comparative gene expression analysis of the
parental and knock-in clone. Expression profile differences of commonly associated epithelial and mesenchymal genes by microarray are shown by
heat map for a ratio of gene expression levels (H1047R A to parental). (B) Effects of GDC-0941 and erlotinib combination treatment in parental and
knock-in cell lines. Percent growth inhibition data from a viability assay is shown at EC50 doses of single agent GDC-0941 and 2.5 mM erlotinib after
drug incubation. Each bar indicates mean % inhibition 6SEM from quadruplicate wells.
doi:10.1371/journal.pone.0036402.g002
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36402Figure 3. MCF10A knock-in cells show a more invasive phenotype in 3-D cell culture. (A) Parental and H1047R A cells were cultured for 2
days in the presence or absence of GDC-0941 (0.5 mM), PI103 (0.5 mM), PI3Ki-A/D (2 mM), AKT1/2i (5 mM) or mTOR1/2i (5 mM). (B) A mathematical
distribution of acinar size (area) and shape (shape factor) was used to assess morphology changes with drug treatments on day 2. Data are plotted as
the mean (horizontal line), middle 50% of data (box), and 95% confidence interval (lines). Pair-wise comparisons to the DMSO control were done by
Student’s t test. GDC-0941 and PI103 treatments resulted in significant morphology changes in both the parental and H1047R A clone (p,0.02, area
or shape factor). PI3Ki-A/D treatment resulted in significant morphological changes in parental (p,0.006, area) or the H1047R clone (p,0.003, area or
shape factor). Statistical significance was also achieved in the H1047R clone with the AKT1/2i (p,0.0002, area or shape factor) or mTOR1/2i (p=0.03,
shape factor).
doi:10.1371/journal.pone.0036402.g003
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PIK3CA kinase domain mutations and PI3K pathway
signaling
A human mammary epithelial cell line, MCF10A, carrying an
endogenous H1047R PI3K mutation ‘‘knocked in’’ to one allele
[10] was used to investigate cellular changes associated with
oncogenic PIK3CA. Two individual knock-in clones were utilized
and both were found to have increased levels of phosphatidylino-
sitol (3,4,5)-trisphosphate (PIP3), a product of PI3K enzymatic
activity (Figure 1A).
We determined half maximal effective concentrations (EC50s)
with small molecule inhibitors targeting PI3K, Akt, mTOR, and
EGFR in the parental and knock-in clones in a growth inhibition
format assay using CellTiter-Glo (Figure 1B and Table 1).
Specificities and potencies for the compounds are shown in
Table 1. GDC-0941 is a potent inhibitor of all class I PI3K
isoforms, and is currently being evaluated in clinical trials [19].
PI3Ki-A/D is related to GDC-0941, but has reduced potency
against the p110bclass I PI3K isoform [20]. PI103 is a pan class I
PI3K isoform inhibitor and also displays significant potency
against mTOR and DNA-PK [21,22]. To evaluate the effects of
inhibition downstream of PI3K, but still in the PI3K pathway, we
utilized inhibitors of Akt and mTOR kinase. AKT1/2i selectively
inhibits Akt1 and Akt2 [23,24], while mTOR1/2i is a selective
inhibitor of mTOR kinase, thus blocks the signaling of both
TORC1 and TORC2 complexes [15,25]. Surprisingly, the
parental line and two independent knock-in clones displayed
similar sensitivities to inhibitors in this 2-dimensional assay format
(Figure 1B and Table 1). GDC-0941 EC50 concentrations of
0.5 mM for parental, H1047R A and H1047R B clones were
utilized in subsequent experiments.
Consistent with PI3K mutation activating the signaling path-
way, the phosphorylation levels of several downstream pathway
components were significantly increased in the H1047R clones
compared to parental cells (Figure 1C). The phosphorylation of
Akt was increased, as well as other markers of pathway activity
including phospho-PRAS40, phospho-P70S6K, phospho-S6, and
phospho-GSK3b. These data are consistent with a recent study
showing enhancement of multiple downstream signaling effects
with an endogenous PI3K mutation [12]. When the cells were
treated with GDC-0941 at 0.5 mM concentrations for 1 or
4 hours, phosphorylation of all the downstream markers was
reduced (Figure 1C). These included proximal pathway markers
such as phospho-Akt and markers further downstream in the PI3K
pathway such as phospho-GSK3b.
Augmented PTEN/PI3K pathway signaling is expected to lead
to increased cell proliferation [12]. We therefore investigated the
proliferative capacity of the parental and knock-in clones. When
growth was measured for 48 hours, we discovered that knock-in
clones proliferated approximately 2–3 fold faster than the parental
cells (Figure 1D). This increase is far less than described by Isakoff
et al [26] using retrovirally over-expressed PI3K in the same
parental cell-type (MCF10A), nor do we see tumorigenicity in soft
agar (data not shown). Our data are consistent, however, with
other single oncogene knock-in phenotypes such as Ras [10,11],
where more subtle effects are observed in mutant knock-in cells
compared to cells with protein over-expression. Treatment with
GDC-0941 at EC50 and 36 EC50 concentrations strongly
inhibited the growth of both parental and knock-in clones
(Figure 1D).
To further explore the phenotypic and biological consequences
of the kinase domain mutation, a microarray study was performed
comparing untreated parental vs. mutant cells to those treated for
4 hours with an EC50 concentration of GDC-0941. Analysis of
common cell cycle genes correlated with the increased prolifera-
tion we observed in the cell growth assay (Figure S1 and Table S1).
Levels of cyclin D1, for example, were significantly increased in
the knock-in cell line suggesting that these cells were advancing
more rapidly through the G1 phase of the cell cycle. A reduction
in the expression level of the cell cycle inhibitor p27
Kip1 was
observed, also suggestive of an increased proliferative capacity.
GDC-0941 treatment normalized the expression of cyclin D1 and
p27
Kip1 as well as other genes differentially regulated by mutant
PIK3CA (Figure S1). Altogether, these data show the PI3K kinase
domain mutation drives pathway activation, increases signaling
and proliferation, and GDC-0941 blocks these effects. However,
there was no discernable differential ‘gene-addiction’ effect when
comparing mutant versus wild-type cell growth, prompting
investigation into other phenotypes for their sensitivity and
selectivity to PI3K inhibitors.
PI3K pathway activitation and epithelial-to-mesenchymal
transition
MCF10A cells have a typical epithelial morphology when
cultured on plastic. In contrast to the parental MCF10A cells, the
knock-in clones have a spindle-like morphology more representa-
tive of fibroblasts (Figure S2). Within a tumor, these morphological
Figure 4. siRNA knockdown of p110a, Akt or mTOR pheno-
copies small molecule inhibitor treatments. (A) Knock-in cells
(H1047R A) were transfected with the indicated siRNAs and plated in
the 3-D culture assay for 5 days. (B) Assessment of siRNA knockdown by
Western blot in the knock-in clone (H1047R A) 48 hours after
transfection (NT=Non-targeting control siRNA).
doi:10.1371/journal.pone.0036402.g004
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ness and metastasis. The morphological changes are also
characteristic of cells that have undergone the epithelial-to-
mesenchymal transition (EMT). PI3K pathway alterations have
been identified as a central feature of EMT in tumor cell lines and
clinical samples [27,28,29,30]. For EMT to occur, complex
changes in gene expression are necessary [31,32]. Gene expression
profiles were analyzed for the parental cells and the PI3K H1047R
clone, and profiles associated with EMT were significantly
changed. In the H1047R cells the majority of epithelial genes
had decreased RNA expression compared to parental cells and
conversely, the majority of the mesenchymal genes had increased
expression compared to the parental cells (Figure 2A and Table
S1). Through PI3K signaling, the balance between Akt1 and Akt2
rather than the overall activity of Akt has been shown to regulate
the EMT response [33,34,35].
Resistance to EGFR inhibitors has been associated with the
mesenchymal subtype [36,37]. Consistent with this effect, the
MCF10A parental cells were sensitive to the EGFR inhibitor
erlotinib, while the PIK3CA H1047R knock-in clones were highly
resistant (Figure 1B, Figure 2B, and Table 1). The resistance to
erlotinib associated with the mesenchymal phenotype is also
consistent with clinical data [38]. With the hypothesis that the
EMT is driven through the PI3K pathway, we then tested the
hypothesis that erlotinib resistance could be overcome by
combining erlotinib with GDC-0941. In both parental and
knock-in clones an improvement in potency was achieved when
the two drugs were used in combination (Figure 2B).
Invasiveness and the PIK3CA kinase domain mutation
Increases in invasive potential are commonly associated with
EMT in preclinical models. Utilizing a microarray signature for
invasiveness [39] it was found that some of the RNA expression
levels were altered in the H1047R clones versus parental cells
(Figure S3 and Table S1). Indeed, data from recent clinical studies
found frequent PIK3CA mutations in lymph node positive tumors,
suggesting increased metastasis for this genotype [40,41,42].
The invasive potential of malignant cells can be reliably
distinguished when cultured in the presence of a laminin-rich
basement membrane [43]. Using this 3-D culture method, breast
Figure 5. MCF10A knock-in cells show enhanced migration through matrigel. (A) Cells were plated under the conditions indicated and
allowed to migrate for 24 hours. Representative images for each condition are shown. (B) Quantification of migrated cells in triplicate wells.
doi:10.1371/journal.pone.0036402.g005
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distinct morphologies [43]. MCF10A cells form colonies of a
‘‘round’’ morphology with apical-basal polarity in 3-D culture,
and cells with this morphology are categorized as non-invasive.
When assessed in 3-D culture, the parental MCF10A colonies
were round with robust cell-cell adhesion (Figure 3A). In contrast,
the PI3K H1047R knock-in clones displayed a highly motile
phenotype wherein individual cells grow into highly elongated
projections or branches. This morphology is characteristic of the
highly invasive ‘‘Stellate’’ group. PI3K inhibitor treatments
dramatically reversed this aggressive phenotype of the H1047R
knock-in clone back into a morphology resembling parental cells
(Figure 3A), without impacting the viability of the acinar foci (data
not shown). This overt phenotype and drug induced reversion has
been confirmed in an independent source of MCF10A cells (11)
that were mutated for PI3K (Figure S4).
Given that acini treated with the inhibitors displayed noticeable
qualitative changes in morphogenesis, we utilized quantitative
methods to more accurately assess phenotypes as a measure of
drug efficacy [18]. Phase-contrast images of MCF10A parental
and the knock-in clone were analyzed for total area and shape.
The shape factor is a measure of morphology and yields values
from 0 (flat line) to 1 (perfect circle). By these analyses, the three
different PI3K inhibitors decreased the area and increased the
shape factor, especially in the knock-in clone (Figure 3B).
Significantly, these results indicate that increases in PTEN/PI3K
pathway signaling promote an invasive phenotype, and that PI3K
inhibition can reverse this effect.
In order to determine if inhibition of downstream signaling in
the PI3K pathway would be effective at overcoming oncogene
addiction, Akt and mTOR kinase inhibitors were assessed for
effects on H1047R cells. Unexpectedly, the Akt and mTOR
inhibitors, even at high concentrations of 5 mM, did not reduce the
Figure 6. PI3K signaling responses to PI3K pathway inhibition. (A) Knock-in cells (H1047R A) were cultured with inhibitors at concentrations
used in the 3-D culture assay and analyzed by Western blotting for indicated treatment times. (B) PIP3 levels assessed at 48 hours post treatment with
3-D culture concentrations of inhibitors in the knock-in clone (H1047R A). (C) PI3K and Akt inhibitor effects can be distinguished in 3-D culture
through variations in cellular morphology. Phase contrast images of the knock-in clone (H1047R A) show representative phenotypes of treatment
with 0.5 mM GDC-0941, 5 mM AKT1/2i, or the same compound doses in combination after 2 days in culture.
doi:10.1371/journal.pone.0036402.g006
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changes were being controlled upstream in the PI3K pathway.
Interestingly, the Akt and mTOR inhibitors appeared to have the
opposite effect to PI3K inhibitors, in that the Akt and mTOR
inhibitors increased the invasive phenotype (Figure 3B).
We tested 10 additional breast tumor cell lines in 3-D culture in
the presence or absence of PTEN/PI3K pathway inhibitors. Two
of the cell lines, BT20 and MDA-MB-436, showed invasive
morphologies in 3-D and were similar to the H1047R knock-in
clones in response to PTEN/PI3K pathway inhibitors (Figure S5).
Both of the cell lines have alterations in the PTEN/PI3K pathway.
BT20 cells have the same PI3K kinase domain mutation
(H1047R) as MCF10A knock-in cells, while the MDA-MB-436
cell line has lost expression of the tumor suppressor PTEN [15,44].
Both cell lines have also been described as mesenchymal
[31,45,46]. Thus, both increased pathway signaling and the
mesenchymal subtype may be required for the invasive morphol-
ogy.
To confirm morphology changes discovered using small
molecule inhibitors, siRNA experiments were carried out to knock
down p110a, Akt1/2, or mTOR, in the knock-in MCF10A clone.
Similar to findings with small molecule inhibitors, the p110a
directed siRNA clearly decreased stellate structures while knock-
down of Akt or mTOR resulted in a significant promotion of
invasive morphologies (Figure 4A). The effectiveness of siRNA
knockdown of these targets is shown in Figure 4B. Overall,
morphology changes in the parental cells with PI3K pathway
inhibition were minimal in 3-D culture, likely due to decreased
basal PI3K pathway activity.
The process of tumor metastasis and invasion involves the
migration of individual cells from the primary tumor through a
basement membrane. The cells then enter the bloodstream or
lymphatic vessels and ultimately seed into a distant organ site [47].
We investigated motility of the MCF10A isogenic cells through
matrigel and found that the H1047R knock-in clone migrated
approximately 5-fold faster than the parental clones over 24 hours
(Figure 5). In the migration assay, treatments with inhibitors also
showed a similar trend to the phenotypes observed in matrigel.
GDC-0941 decreased the number of migrated knock-in cells,
while AKT1/2i increased the number of migrated knock-in cells.
Effects of GDC-0941 and AKT1/2i were not significant for the
parental cells in the migration assay (data not shown). Thus, the
morphologies observed in 3-D culture are due, at least in part, to
increased cell motility.
The effect of compounds on downstream PI3K pathway
markers was investigated in the H1047R knock-in clone at the
same drug concentrations and media conditions used in the 3-D
culture assay (Figure 6A). The PI3K pathway inhibitors all showed
similar inhibition of phospho-Akt
Ser473 and phospho-IRS1
Ser612.
As expected, amounts of PIP3 decreased with PI3K inhibitor
treatments (Figure 6B). In contrast, cellular PIP3 levels were
elevated above basal levels upon treatment with either an Akt or
mTOR kinase inhibitor. Taken together, these data support the
hypothesis that PI3K pathway blockade promotes feedback to
PIP3, but if PI3K itself is not inhibited, PIP3 levels can accumulate
and promote the invasive morphology. In support of this
hypothesis, when GDC-0941 was combined with AKT1/2i in 3-
D culture, the morphology resembled GDC-0941 treatment alone
(Figure 6C). Significantly, these findings suggest a potential
therapeutic difference between PI3K and Akt inhibitors in their
effectiveness at controlling invasion and metastasis. We are
currently investigating the signaling mediators of these differences.
When cultured on plastic (2-D), the H1047R knock-in clones
displayed increased PI3K pathway activity and proliferation, but
oncogene addiction was not observed. We found that the H1047R
mutation was linked to EMT by analysis of epidermal and
mesenchymal gene signatures, rescue of EGFR inhibitor resistance
by a PI3K inhibitor, and acinar morphologies in 3-D culture.
PI3K inhibitors and siRNA reversed the morphologies in 3-D
culture, but mTOR and Akt inhibitors and siRNA worsened the
invasive phenotype. This was due to increased feedback to PIP3
that cannot be controlled by inhibitors downstream of PI3K.
These data suggest that invasion may be the most relevant
phenotype to assess for PI3K oncogene addiction. Consistent with
this hypothesis is a previous in vivo study that showed knocking-
out mutant PIK3CA in a fully tumorigenic colon cancer cell line
had more pronounced effects on metastasis than on primary tumor
growth [48]. Not only do these results demonstrate invasion is a
core phenotype of mutant PI3K, but that only direct PI3K-
inhibitors are effective in reversing it, and targeting downstream
nodes in the pathway can in fact promote the invasive phenotype.
In summary, the H1047R mutant of PIK3CA increases PTEN/
PI3K pathway signaling and markers of EMT and cell migration
phenotypes in isogenic breast epithelial cell lines. Notably,
pathway targeted agents dramatically diverge in their ability to
revert these phenotypes, with direct PI3K inhibitors representing
the optimal intervention node for mutant PI3K cancers. These
data suggest that invasion-based readouts and biomarkers may be
the most appropriate end points to reveal the ‘gene-addiction’
responses to PI3K inhibitors in the clinic.
Supporting Information
Figure S1 Differential mRNA expression of cell cycle
genes in triplicate microarray samples. Error bars indicate
6SEM.
(TIF)
Figure S2 Phase-contrast images of the parental and
knock-in clones in culture.
(TIF)
Figure S3 MCF10A cells with a PI3K mutation show
gene expression patterns associated with invasiveness.
Comparative gene expression analysis of the MCF10A parental
and H1047R clone A. Microarray differences presented as a heat
map are indicated as ratios (H1047R A to parental) for genes
commonly linked to invasiveness.
(TIF)
Figure S4 Horizon MCF10A H1047R knock-in cells show
a more invasive phenotype in 3-D cell culture. Parental
and H1047R knockin clones were cultured for 24 hours in Geltrex
Reduced Growth Factor Basement Membrane Matrix (Invitrogen)
in the presence or absence of GDC-0941 (1 mM). This type of
matrigel was used to augment the invasive morphologies of the
H1047R knockin clones.
(TIF)
Figure S5 GDC-0941 inhibits invasive morphologies in
breast tumor cell lines. (A) BT20 cells were cultured for
24 hours in the presence or absence of inhibitors at EC50 viability
concentrations (GDC-0941 (0.6 mM), PI103 (0.4 mM), PI3Ki-A/D
(1.2 mM), AKT1/2i (3 mM), or mTOR1/2i (2 mM)). (B) MDA-
MB-436 cells were cultured for 48 hours in the presence or
absence of inhibitors at EC50 viability concentrations (GDC-0941
(0.8 mM), PI103 (0.5 mM), PI3Ki-A/D (1.5 mM), AKT1/2i
(3.8 mM), or mTOR1/2i (1.7 mM)).
(TIF)
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analysis.
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